M-VAC protocol

08/01/1989 - "These results indicate that the M-VAC regimen is effective in patients with advanced upper urothelial malignancy. "
01/01/1992 - "These results suggest that the M-VAC regimen holds promise for the treatment of advanced metastatic transitional cell cancer as well as non-transitional cell cancer of the urothelium."
09/01/2002 - "The primary local tumor is treated by radical surgery or radiation therapy, while systemic involvement requires polychemotherapy according to the M-VAC protocol. "
02/15/1999 - "[Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer]."
11/01/1993 - "Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer."

01/01/2007 - "Chemotherapy by M-VAC protocol in progressive bladder carcinoma treatment."
04/01/1994 - "Between June 1987 and December 1990, systemic chemotherapy following an M-VAC protocol was applied to 38 patients with infiltrant vesical carcinoma (T2-T4). "
08/01/1989 - "This study demonstrates that the M-VAC regimen is effective in the invasive bladder carcinoma with or without lymph nodes metastases. "
08/01/2011 - "The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen."
06/01/2007 - "The methotrexate, vinblastine, doxorubicin, cisplatin (M-VAC) regimen has been considered as standard treatment of metastatic bladder carcinoma till recent years. "

09/01/1998 - "Thirteen patients with high stage, metastasis or recurrences were treated after operation with the M-VAC or modified M-VAC regimen as preventive, adjuvant and/or salvage chemotherapy. "
08/01/1989 - "This study demonstrates that the M-VAC regimen is effective in the invasive bladder carcinoma with or without lymph nodes metastases. "
07/01/1996 - "54 patients without distant metastases (T2-T3b, N0-X, M0) received 3 cycles of neoadjuvant chemotherapy according to the MVAC protocol (methotrexate, vinblastine, doxorubicin and cisplatin) after transurethral resection (TUR) followed by cystectomy. "

01/01/1998 - "50 patients with advanced transitional cell carcinoma of the bladder were treated with the M-VAC regimen at the Hôpital Cochin (Paris, France) between December 1989 and February 1995. "
12/01/1993 - "Pathologic response and long term results of preoperative M-VAC regimen in regionally advanced transitional cell carcinoma of the bladder."
01/01/1993 - "Local response and long-term results of preoperative M-VAC regimen in regionally advanced transitional cell carcinoma of the bladder."
11/01/1992 - "We report a case of CA19-9 producing transitional cell carcinoma of the right ureter effectively responsive to combination chemotherapy (methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) regimen) in a 53-year-old woman. "
12/15/1989 - "Of 133 patients with advanced urothelial tract cancer given methotrexate (MTX), vinblastine (VBL), Adriamycin (ADR) (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (DDP) (M-VAC regimen), significant tumor regression occurred in 72% +/- 8% of 121 with transitional cell carcinoma (TCC) evaluable for response. "

11/01/1992 - "The M-VAC regimen has become the dominant combination for the treatment of advanced bladder cancer; its use in an adjunctive setting is a logical progression. "
07/01/1989 - "M-VAC regimen in murine bladder tumors."
01/01/1998 - "High incidence of brain metastases in patients treated with an M-VAC regimen for advanced bladder cancer."
05/01/1997 - "The M-VAC regimen (methotrexate, vinblastine, doxorubicin and cisplatin) is widely used in the treatment of advanced or metastatic bladder cancer. "